Controversy exists over changes in tolerability and response to medications across the life span.
Some variations in tolerability may be due to the size of the macrocyclic ring and the presence of different esters.
Limitations of the present study are the single-blind design and the lack of power to detect differences in tolerability.
These combinatorial therapies are difficult to administer for both patient and caregiver and often result in tolerability issues.
Sertraline was significantly superior in tolerability with less discontinuations due to adverse events (10.3%) compared with the imipramine group (24.4%) (P=.004).
Improvements in tolerability and safety have been achieved, without compromises in effectiveness, primarily via hormone dosage reductions and the development of several new progestins.
Although the efficacy of medications for attention-deficit/hyperactivity disorder (ADHD) is well demonstrated in clinical trials, substantial numbers of patients fail to remain on therapy, and there is tremendous variability in tolerability and treatment acceptance.
As this trial involves switching formulations of the same compound, we expect to find only small differences in efficacy but significant differences in tolerability and quality-of-life measures.
The classical and modified MCT ketogenic diets are equally effective and differences in tolerability are not statistically significant.
One hundred children aged 1 to 6 years were sequentially assigned to 3 cohorts of 20, 40 and 40 participants with stratification for age by 2-year increments (1 2 years, 3 4 years, and 5 6 years) to ensure that the study groups were balanced by age in case of age-related differences in tolerability or immunogenicity.
No important differences in tolerability were found.
